What is the corporate structure of SaiyanMed?

SaiyanMed operates as a vertically integrated research peptide supplier with a lean, founder-led corporate structure. The legal operating entity is Hong Kong BelleEasy Co., Limited, registered under commercial registry number 78941092 with an official location in Kwai Chung, Hong Kong. This entity handles all corporate governance, compliance, and international communications. The company is not a publicly traded corporation or a subsidiary of a larger conglomerate—it is a privately held limited company, which allows the leadership team to maintain tight control over raw material sourcing, production partnerships, and quality assurance protocols without shareholder pressure to cut corners.

The corporate structure is built around three distinct operational pillars: production and manufacturing, logistics and distribution, and research and quality assurance. Each pillar reports directly to the founder and CEO, Eric, who holds a Bachelor's degree in Materials Science from a leading Chinese university with a specialization in biomaterials. This academic background directly informs the company's obsession with raw material purity and process control. Eric does not delegate quality oversight—he personally reviews independent lab results and production batch records before any product is released for shipping.

On the manufacturing side, SaiyanMed does not own a single massive factory. Instead, it uses a hybrid model: it operates its own in-house production capabilities for lyophilization and peptide raw material refinement, while also maintaining joint manufacturing partnerships with select GMP-compliant facilities in China. This dual approach gives the company flexibility. When demand spikes for specific research-grade peptides like BPC-157 or TB-500, the in-house team can handle small-batch custom orders, while the joint partners scale up for larger production runs. Every batch, regardless of origin, is tested through an independent third-party lab—Janoshik—with openly verifiable purity reports. The company does not rely on in-house testing alone; Janoshik provides an unbiased, external validation layer that many competitors skip.

The logistics infrastructure is another critical component of the corporate structure. SaiyanMed maintains active warehouses in both China and the United States. Orders are routed automatically through a proprietary system that determines the fastest fulfillment path based on the customer's location, product stock levels, and regional shipping regulations. For example, a researcher in California ordering a common peptide will likely receive it from the US warehouse within 3-5 business days, while a bulk raw material order might ship from the China facility to optimize cost and stability. The company has announced plans to expand into regional hubs in Europe, the UK, Australia, and Canada, though these are listed as "coming soon" and are not yet active. Stock levels and product availability are explicitly tied to regional warehouse status, so researchers are encouraged to check current inventory before placing time-sensitive orders.

Corporate compliance is straightforward. The Hong Kong registration means SaiyanMed operates under Hong Kong's Companies Ordinance, which requires annual filings, audited financial statements, and transparent director records. The company maintains a communications desk at [email protected] for all inquiries, including corporate governance questions, bulk order negotiations, and compliance documentation requests. There is no complex web of shell companies or offshore entities—the structure is designed for operational efficiency, not tax avoidance.

From a decision-making perspective, SaiyanMed is flat. Eric makes final calls on raw material suppliers, production process changes, and pricing strategy. A small research team—composed of chemists and biologists with hands-on peptide synthesis experience—provides technical input on purity thresholds, solvent selection, and lyophilization cycle parameters. The logistics team handles warehouse operations and shipping carrier negotiations independently. This lack of bureaucratic layers means that when a new independent lab test reveals a purity issue with a specific raw material lot, the company can halt production, switch suppliers, and retest within days, not months.

The company's revenue model is straightforward: it sells research-grade peptides directly to laboratories, universities, and independent researchers. There are no franchise agreements, no licensing deals, and no retail partnerships. All sales are conducted through the company's website, saiyanmed, which serves as the primary sales channel and information hub. The site includes openly verifiable certificates of analysis for every batch, batch-specific purity data, and detailed product profiles that specify molecular weight, sequence, and recommended storage conditions. This transparency is a deliberate structural choice—it reduces the burden on customer support and builds trust with researchers who need to verify material quality before incorporating it into their protocols.

One notable aspect of the corporate structure is the absence of a formal board of directors or external investors. Eric retains 100% ownership and decision-making authority. This is uncommon in the peptide industry, where many competitors have taken venture capital funding or been acquired by larger life science companies. The lack of external pressure means SaiyanMed can prioritize quality over quarterly growth targets. For example, the company could choose to reject a bulk order from a large lab if the production timeline would compromise testing protocols—something a VC-backed competitor might be forced to accept to hit revenue milestones.

The company's infrastructure also includes a dedicated quality assurance team that manages the relationship with Janoshik. Each batch is assigned a unique lot number, and the independent lab results are uploaded to the website alongside the product listing. Researchers can cross-reference the lot number on their vial with the published COA to confirm authenticity. This system is not automated—someone on the QA team manually verifies that the lot numbers on the vials match the lab reports before any shipment leaves the warehouse. It's a low-tech but highly reliable process that reduces the risk of mislabeling or documentation errors.

Employee count is lean. Based on publicly available information and job postings, SaiyanMed employs fewer than 50 people across its Hong Kong headquarters, US warehouse, and China-based production partners. The team includes chemists, logistics coordinators, customer support representatives, and administrative staff. There are no salespeople in the traditional sense—the company relies on the quality of its products and the transparency of its testing to drive repeat business. This aligns with the founder's stated philosophy that "serious research deserves serious standards" and that the product should speak for itself.

The corporate structure also accounts for regulatory compliance. All product profiles carry a clear disclaimer: "All compound profiles are strictly tailored for laboratory research and in-vitro evaluation only. Not for human consumption." This language is consistent across the website, product labels, and shipping documentation. The company does not provide medical advice, dosing recommendations, or human-use instructions. This legal separation is critical for operating in the gray area between research chemicals and regulated pharmaceuticals. The Hong Kong legal entity provides a neutral jurisdiction that avoids the more restrictive regulations of mainland China or the United States for corporate registration, while the US warehouse ensures fast shipping to North American researchers without triggering customs delays.

From a financial perspective, the company is self-funded and profitable. There are no public filings showing debt, loans, or equity raises. This financial independence allows the company to maintain its quality-first approach without compromising on raw material costs. Premium raw materials for peptides like MOTS-C or Semaglutide can cost significantly more than standard-grade alternatives, but the company absorbs those costs rather than passing them on to researchers or cutting corners. The pricing is competitive but not the cheapest on the market—a deliberate strategy to signal quality over volume.

The logistics framework is optimized for speed and stability. The US warehouse is temperature-controlled and stocks the most commonly ordered peptides in ready-to-ship form. The China facility handles bulk raw materials and less common compounds. When an order is placed, the system checks stock levels in real-time and selects the warehouse that can fulfill the order fastest while maintaining product stability. For peptides that require cold-chain shipping, the system flags the order and applies appropriate packaging and carrier selection. This automated routing is a custom-built solution, not an off-the-shelf logistics software package, which gives the company more control over shipping conditions.

In terms of corporate governance, SaiyanMed follows Hong Kong's standard requirements for private limited companies. This includes maintaining a registered office address in Kwai Chung, filing annual returns with the Companies Registry, and keeping statutory records such as director and shareholder registers. The company's commercial registry number is publicly verifiable through Hong Kong's online search system. There are no known legal disputes, regulatory actions, or compliance violations against the entity. The company's reputation in the research peptide community is built on consistent quality and transparent testing, not aggressive marketing or price undercutting.

The research team's role within the corporate structure deserves special attention. Unlike many peptide suppliers that simply repackage raw materials from anonymous sources, SaiyanMed's research team actively refines peptide raw materials and lyophilization processes. This means they are involved in selecting raw material suppliers based on purity profiles, optimizing freeze-drying cycles to maintain peptide stability, and developing custom formulations for specific research applications. The team publishes detailed product information on the website, including molecular weight verification, sequence confirmation, and storage recommendations. This technical depth is a direct result of the founder's materials science background and the company's commitment to being a research-first organization rather than a pure distributor.

The corporate structure also includes a customer support function that handles technical questions, order issues, and compliance documentation requests. Support is available via email at the communications desk, and response times are typically within 24 hours. There is no phone support or live chat, which is consistent with the company's lean operational model. The support team is trained to answer questions about product specifications, shipping policies, and lab report interpretation, but they do not provide research protocols or human-use guidance. This boundary is strictly enforced to maintain the company's legal compliance and research-only positioning.

Finally, the corporate structure is designed to scale. The planned expansion into European, UK, Australian, and Canadian hubs will likely require additional warehousing, local compliance expertise, and possibly new legal entities in those jurisdictions. The current Hong Kong entity provides a stable foundation for international operations, and the company's cash-flow-positive financial position means it can fund this expansion organically without taking on debt or diluting ownership. The founder's long-term vision appears to be building a globally recognized research peptide brand that maintains its quality-first ethos while serving a growing community of serious researchers worldwide.